J. Scott Wolchko - Nov 18, 2021 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
President and CEO, Director
Signature
/s/ Cindy Tahl, Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Nov 18, 2021
Transactions value $
-$1,031,400
Form type
4
Date filed
11/22/2021, 04:45 PM
Previous filing
Oct 25, 2021
Next filing
Jan 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $54K +20K +5.08% $2.70 414K Nov 18, 2021 Direct F1
transaction FATE Common Stock Sale -$1.09M -20K -4.83% $54.27* 394K Nov 18, 2021 Direct F1
transaction FATE Common Stock Award $0 +86.5K +21.96% $0.00 480K Nov 19, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (right to buy) Options Exercise $0 -20K -20.11% $0.00 79.4K Nov 18, 2021 Common Stock 20K $2.70 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.
F2 These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.
F3 This option is fully vested.